secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001193125-24-279016
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options
--------------------------------------------------------------------------

- Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.
- Compensation: $500k base salary, 40% bonus target, inducement options for 100,000 shares vesting over 4 years.
- Ledell previously COO at AVEO Oncology, Enzyvant Therapeutics, Compass Therapeutics, and Horizon Discovery Group.
- Appointment supports KalVista's preparation for potential sebetralstat launch (HAE); PDUFA goal date June 17, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/0001193125-24-279016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/d866245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-279016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer